F-PSA/T-PSA比值与磁共振联合直肠超声经会阴前列腺穿刺对提高早期前列腺癌检出率的意义  

Significance of F-PSA/T-PSA Ratio Combining Magnetic Resonance(NMR)and Rectal Ultrasound Via Perineum Prostate Biopsy to Improve Early Detection of Prostate Cancer

作　　者：梁阳冰[1,2] 黄向华[1,2] 覃斌[1,2] 李长赞[1,2] 吴清国[1,2] 梁毅文[1,2] 黄寿付[1,2] 张剑歌[1,2] 

机构地区：[1]广西省贵港市人民医院 [2]广西医科大学第八附属医院,广西贵港537100

出　　处：《中国医学创新》2015年第13期130-132,共3页Medical Innovation of China

摘　　要：目的:探讨F-PSA/T-PSA比值与磁共振联合直肠超声经会阴前列腺穿刺对提高早期前列腺癌检出率的意义。方法:选取2009年1月-2013年9月期间本院收治的86例疑似前列腺结节的前列腺穿刺患者为研究对象,根据其临床资料进行回顾性分析与总结,探讨F-PSA/T-PSA比值与磁共振联合直肠超声经会阴前列腺穿刺对提高早期前列腺癌检出率的意义。结果:血清F-PSA/T-PSA、磁共振、TURS三者联合检查的符合率、敏感性、特异性明显高于三者单独检测,三者联合检查与单独检查比较差异具有统计学意义(P<0.05)。结论:F-PSA/T-PSA比值与磁共振联合直肠超声经会阴前列腺穿刺对提高早期前列腺癌检出率具有重要的临床诊断意义,可以提高诊断正确率,为患者的早期治疗提供可靠依据,值得在临床实践中广泛的应用和推广。Objective：To explore the significance of F-PSA/T-PSA ratio in combination with magnetic resonance （NMR）and rectal ultrasound via the perineum prostate biopsy to improve early detection of prostate cancer.Method：86 patients with suspected prostate biopsy of prostate nodules were selected in our Hospital as research subjects from January 2009 to September 2013,whose clinical data were retrospectively analyzed and summarized,the significance of F PSA/T PSA ratio combing magnetic resonance（NMR）and rectal ultrasound via the perineum prostate biopsy to improved early detection of prostate cancer were discussed.Result：The coincidence rate,sensitivity and specificity of joint examinations of serum F-PSA/T-PSA,magnetic resonance and TURS were obviously higher than that of the separate three tests abovementioned,the differences were statistically significant（P〈0.05）.Conclusion：F-PSA/T-PSA ratio combining magnetic resonance（NMR）and rectal ultrasound via the perineum prostate biopsy to improve early detection of prostate cancer delivers important clinically diagnostic significance,it can improve the diagnostic accuracy,and provide reliable basis for early treatment of patients,it is worth of wide application in clinical practices and promotion.

关 键 词：磁共振 F-PSA/T-PSA比值 前列腺癌 超声检查 

分 类 号：R737.25[医药卫生—肿瘤]